Abstract：
Neuroinflammation has emerged as a shared molecular mechanism in epilepsy and cognitive impairment, offering new insights into the complex interplay between immune responses and brain function. Evidence reveals involvement of High mobility group box 1 (HMGB1) in blood-brain barrier disruption and correlations with epilepsy severity and drug resistance. While anti-inflammatory treatments show promise, translating these discoveries faces challenges in elucidating mechanisms and developing reliable biomarkers. However, strategically targeting neuroinflammation and HMGB1-mediated inflammation holds therapeutic potential. This review synthesises knowledge on HMGB1 and related biomarkers in epilepsy and cognitive impairment to shape future research and treatments targeting these intricate inflammatory processes.
摘要：
神经炎症已成为癫痫和认知障碍的共同分子机制，为免疫反应和大脑功能之间复杂的相互作用提供了新的见解。证据显示高迁移率族蛋白1（HMGB1）参与血脑屏障破坏，并与癫痫严重程度和耐药性相关。虽然抗炎治疗显示出希望，翻译这些发现在阐明机制和开发可靠的生物标志物方面面临挑战。然而,战略性靶向神经炎症和HMGB1介导的炎症具有治疗潜力。这篇综述综合了关于癫痫和认知障碍中HMGB1和相关生物标志物的知识，以塑造针对这些复杂炎症过程的未来研究和治疗。
